# Program 1 Phase V0 - Scope and Non-Production Boundaries

Phase V may prototype boundaries. Phase V may not authorize production or real-data use. Phase V may not create clinical workflow enforcement.

## Definitions

| Term | Definition | Phase V status |
| --- | --- | --- |
| Prototype boundary | A non-production artifact used to model or test future control behavior without authorizing clinical, real-data, or production use. | allowed as documentation only |
| Production enforcement | Runtime behavior that controls production access, workflow, deployment, or operation. | not allowed |
| Passive metadata | Definitions, constants, schemas, or functions that are not wired into production authorization, workflow enforcement, or clinical write behavior. | allowed only if non-authorizing; not used in Phase V |
| Runtime authorization | Actual enforcement that permits or denies user actions in production workflows. | not implemented |
| Audit event design | Documentation of future event categories, fields, and traceability requirements. | documented only |
| Production audit logging | Validated, complete, tamper-resistant, reviewable audit event capture for production use. | not implemented |
| Real-data boundary detection | A future control concept or prototype check intended to identify or block real-data/PHI/PII boundary risk. | documented only |
| Real-data processing authorization | A separate future legal/governance/security decision. | not granted |

## Non-production boundary

Phase V performs non-production prototype documentation only. It does not create runtime controls, auth/authz/RBAC, audit logging, data ingestion, upload/import routes, clinical write workflows, production deployment changes, legal/compliance approval, validation approval, or go-live authorization.

All existing prohibitions remain active:

- no production approval
- no real patient data approval
- no PHI/PII processing approval
- no live clinical deployment
- no runtime approval, clearance, or override capability
- no patient messaging
- no appointment mutation
- no Task engine or Outcome Evidence
- no workflow enforcement
- no new clinical write workflow
